John Fair - Dare Bioscience Chief Business Officer
| DARE Stock | USD 2.40 0.01 0.42% |
Executive
Mr. John Fair is Chief Business Officer of the Company. Mr. Fair has over twenty years of experience in the biopharmaceutical industry in business and corporate development roles. Most recently, Mr. Fair was President and COO of Evofem Inc., a latestage, specialty pharmaceutical company focused on women reproductive health. He was part of the management team that secured a global license to the Nestorone oneyear contraceptive vaginal ring, successfully divested the OTC women hygiene franchise and closed series C and D funding. Prior to joining Evofem, Mr. Fair held seniorlevel roles at WomanCare Global, a UK based global women health entity. During his tenure he was part of the management team that collaborated with FHI 360 to commercialize Sinoimplant in select regions and secured donor funding from the US Agency for International Development since 2018.
| Age | 53 |
| Tenure | 7 years |
| Phone | 858 926 7655 |
| Web | https://darebioscience.com |
Dare Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.8698) % which means that it has lost $0.8698 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (9.9469) %, meaning that it created substantial loss on money invested by shareholders. Dare Bioscience's management efficiency ratios could be used to measure how well Dare Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Martin Lafontaine | vTv Therapeutics | N/A | |
| Barry Brown | vTv Therapeutics | 64 | |
| Mark Rubinstein | Achieve Life Sciences | N/A | |
| Richard Jacroux | ENDRA Life Sciences | 57 | |
| David JD | Q32 Bio | N/A | |
| Lee MBA | Q32 Bio | 44 | |
| Kelly MHA | CervoMed | 61 | |
| Marinus Verwijs | CervoMed | 49 | |
| Irina Pestrikova | ENDRA Life Sciences | 38 | |
| Claudia MD | CervoMed | 59 | |
| Ziad Rouag | ENDRA Life Sciences | N/A | |
| Jaime Xinos | Achieve Life Sciences | 48 | |
| Maria MPH | Q32 Bio | N/A | |
| Steve Freeman | ENDRA Life Sciences | N/A | |
| Srikanth MD | Connect Biopharma Holdings | N/A | |
| Craig Donnelly | Achieve Life Sciences | N/A | |
| Lisa CPA | Connect Biopharma Holdings | 48 | |
| Kimberly Manhard | Connect Biopharma Holdings | 65 | |
| Curtis Lockshin | Xenetic Biosciences | 64 | |
| Elizabeth Keiley | vTv Therapeutics | 59 | |
| Dr Cobuzzi | CervoMed | 60 | |
Management Performance
| Return On Equity | -9.95 | ||||
| Return On Asset | -0.87 |
Dare Bioscience Leadership Team
Elected by the shareholders, the Dare Bioscience's board of directors comprises two types of representatives: Dare Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dare. The board's role is to monitor Dare Bioscience's management team and ensure that shareholders' interests are well served. Dare Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dare Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sabrina Johnson, President CEO, Secretary, Director | ||
| David Friend, Chief Officer | ||
| MarDee HaringLayton, Chief Officer | ||
| John Fair, Chief Business Officer | ||
| Lisa WaltersHoffert, Executive Officer | ||
| Mark Walters, Vice Operations |
Dare Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dare Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -9.95 | ||||
| Return On Asset | -0.87 | ||||
| Operating Margin | (180.17) % | ||||
| Current Valuation | 14.4 M | ||||
| Shares Outstanding | 8.85 M | ||||
| Shares Owned By Insiders | 1.56 % | ||||
| Shares Owned By Institutions | 9.34 % | ||||
| Number Of Shares Shorted | 1.11 M | ||||
| Price To Earning | (43.44) X | ||||
| Price To Book | 10.75 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Dare Bioscience is a strong investment it is important to analyze Dare Bioscience's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Dare Bioscience's future performance. For an informed investment choice regarding Dare Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dare Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dare Bioscience. If investors know Dare will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dare Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dare Bioscience is measured differently than its book value, which is the value of Dare that is recorded on the company's balance sheet. Investors also form their own opinion of Dare Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Dare Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dare Bioscience's market value can be influenced by many factors that don't directly affect Dare Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dare Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Dare Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dare Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.